Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Glioma × Daclizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 CNS 1

Conditions

Lymphoma 2 Radiation Injuries 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Melanoma 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1 Leukemia, Myeloid, Acute 1 Leukemia 1 Hodgkin Disease 1 Gliosarcoma 1 Glioma 1 Glioblastoma 1

Interventions

Temozolomide 140 Bevacizumab 63 Radiotherapy 54 Magnetic Resonance Spectroscopy 52 Irinotecan 27 Carboplatin 23 Surgical Procedures, Operative 18 Radiation 18 Carmustine 18 Specimen Handling 17 Nivolumab 16 Lomustine 15 Biopsy 15 Aminolevulinic Acid 15 pembrolizumab 12 Radiotherapy, Intensity-Modulated 12 Cyclophosphamide 12 trametinib 11 Topotecan 11 Radiosurgery 11 Erlotinib Hydrochloride 11 fluorodopa F 18 9 IL13-PE38 9 Everolimus 9 ribociclib 8 dabrafenib 8 X-Rays 8 Imatinib Mesylate 8 Filgrastim 8 Etoposide 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00626015 2016-01-21

ZAP IT

Duke University

Phase 1 Completed

Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡